- GSK shelves cough drug acquired in $2B dealMixed Phase 3 data for camlipixant prompted the British pharma to cease development, making the drug the third from its class to fail.BioPharma Dive · 11d ago↗ source
- How well are AI-discovered drugs faring in the clinic?Some of the industry’s most closely-watched AI drugs could provide insight into the success of technology-assisted development.BioPharma Dive · 11d ago↗ source
- GSK culls cough program for drug at the heart of $2B Bellus bet after Phase 3 failCamlipixant, which GSK picked up in its $2 billion buyout of Bellus Health in April 2023, “is unlikely to transform patient care,” the pharma said.BioSpace · 11d ago↗ source